Q1 2026 Neurocrine Biosciences Inc Earnings Call Transcript
Hello, and welcome, everyone joining today's Neurocrine Biosciences Q1 2026 earnings call. (Operator Instructions) Please note, this call is being recorded. We are standing by if you should need any assistance.
It is now my pleasure to turn the meeting over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Thank you, and happy Cinco to mile to everyone. Welcome to Neurocrine Biosciences first quarter 2026 earnings call. Joining me today are Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; Sanjay Keswani, Chief Medical Officer; and Samir Sadanti, Vice President of Strategy and Corporate Development.
During today's call, we will be making forward-looking statements, including statements containing projections regarding future events such as the anticipated closing of our acquisition of Sileno Therapeutics. These statements are subject to certain risks and uncertainties, and our actual results may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
